We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Reports Positive Data on Fitusiran, Givosiran
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced new positive results from an ongoing phase II open-label extension (OLE) study on fitusiran in the treatment of patients with hemophilia A or B, without inhibitors.
A look at Alnylam’s year-to-date share price movement shows that the stock has underperformed the Zacks classified Medical-Biomed/Genetics industry. Share price tumbled 55.8% year to date, compared with the industry’s 25.6% decline.
Coming back to the latest news, data from the study revealed that once-monthly subcutaneous administration of fitusiran led to consistent reduction of antithrombin (AT) and increase in thrombin generation, resulting in a median-estimated annualized bleeding rate (ABR) of 1.0. The candidate was generally well tolerated with no thromboembolic events reported. The company expects to report data from the study at least once every year.
Results were presented at the annual meeting of the American Society of Hematology.
Alnylam also presented positive interim results from Part D of its ongoing phase I study on fitusiran in patients with hemophilia with inhibitors.
The company expects to begin a phase III clinical program on the candidate in early 2017.
We note that Alnylam has a collaboration agreement with Genzyme, a Sanofi (SNY - Free Report) company, for fitusiran.
Moreover, Alnylam announced positive initial results from Cohorts 1 and 2 of Part C of a phase I study on givosiran (ALN-AS1) for the treatment of acute hepatic porphyrias. Findings demonstrated robust and durable reduction of aminolevulinic acid and porphobilinogen, the toxic heme intermediates that are believed to mediate porphyria symptoms and acute attacks.
The company plans to meet with regulatory authorities with the goal of advancing givosiran into a phase III study in late 2017.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.7% year to date.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates have increased from 16 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%. Its share price has surged 67.6% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Alnylam Reports Positive Data on Fitusiran, Givosiran
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced new positive results from an ongoing phase II open-label extension (OLE) study on fitusiran in the treatment of patients with hemophilia A or B, without inhibitors.
A look at Alnylam’s year-to-date share price movement shows that the stock has underperformed the Zacks classified Medical-Biomed/Genetics industry. Share price tumbled 55.8% year to date, compared with the industry’s 25.6% decline.
Coming back to the latest news, data from the study revealed that once-monthly subcutaneous administration of fitusiran led to consistent reduction of antithrombin (AT) and increase in thrombin generation, resulting in a median-estimated annualized bleeding rate (ABR) of 1.0. The candidate was generally well tolerated with no thromboembolic events reported. The company expects to report data from the study at least once every year.
Results were presented at the annual meeting of the American Society of Hematology.
Alnylam also presented positive interim results from Part D of its ongoing phase I study on fitusiran in patients with hemophilia with inhibitors.
The company expects to begin a phase III clinical program on the candidate in early 2017.
We note that Alnylam has a collaboration agreement with Genzyme, a Sanofi (SNY - Free Report) company, for fitusiran.
ALNYLAM PHARMA Price
ALNYLAM PHARMA Price | ALNYLAM PHARMA Quote
Moreover, Alnylam announced positive initial results from Cohorts 1 and 2 of Part C of a phase I study on givosiran (ALN-AS1) for the treatment of acute hepatic porphyrias. Findings demonstrated robust and durable reduction of aminolevulinic acid and porphobilinogen, the toxic heme intermediates that are believed to mediate porphyria symptoms and acute attacks.
The company plans to meet with regulatory authorities with the goal of advancing givosiran into a phase III study in late 2017.
Alnylam currently has Zacks Rank #3 (Hold).
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector include Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.7% year to date.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates have increased from 16 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%. Its share price has surged 67.6% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>